Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

48.16USD
22 Mar 2019
Change (% chg)

$-0.76 (-1.55%)
Prev Close
$48.92
Open
$48.78
Day's High
$49.05
Day's Low
$48.15
Volume
5,364,288
Avg. Vol
4,284,051
52-wk High
$65.87
52-wk Low
$44.30

Select another date:

Tue, Mar 19 2019

U.S. FDA approves Roche's small cell lung cancer treatment

March 18 Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb.

Third Point holds Celgene stock, in bet Bristol-Myers deal will close: source

Daniel Loeb's hedge fund Third Point LLC owns a small stake in Celgene Corp, betting that the proposed $74 billion sale of the biotechnology company to Bristol-Myers Squibb Co will be completed, a person familiar with the matter said on Monday.

Third Point holds Celgene stock, in bet Bristol-Myers deal will close -source

March 11 Daniel Loeb's hedge fund Third Point LLC owns a small stake in Celgene Corp, betting that the proposed $74 billion sale of the biotechnology company to Bristol-Myers Squibb Co will be completed, a person familiar with the matter said on Monday.

Bristol-Myers defends Celgene bet as investor criticism grows

Bristol-Myers Squibb defended its planned $74 billion takeover of Celgene Corp, saying it had carried out a "robust" assessment of the merger after two major investors opposed what could be the largest pharmaceutical deal ever.

UPDATE 4-Bristol-Myers defends Celgene bet as investor criticism grows

March 6 Bristol-Myers Squibb defended its planned $74 billion takeover of Celgene Corp, saying it had carried out a "robust" assessment of the merger after two major investors opposed what could be the largest pharmaceutical deal ever.

Celgene buy best path forward, Bristol-Myers says

March 6 Bristol-Myers Squibb's planned $74 billion takeover of Celgene Corp is the best path forward for value creation, the company said in an investor presentation on Wednesday.

Intellia CEO not involved in Starboard's Bristol-Myers board challenge

NEW YORK Intellia Therapeutics Inc Chief Executive John Leonard, who U.S. drug maker Bristol-Myers Squibb Co said last week was nominated by hedge fund Starboard Value LP to sit on its board, is not affiliated with the effort, an Intellia spokeswoman said on Thursday.

Intellia CEO not involved in Starboard's Bristol-Myers board challenge

NEW YORK Intellia Therapeutics Inc Chief Executive John Leonard, who U.S. drug maker Bristol-Myers Squibb Co said last week was nominated by hedge fund Starboard Value LP to sit on its board, is not affiliated with the effort, an Intellia spokeswoman said on Thursday.

CORRECTED-Intellia CEO not involved in Starboard's Bristol-Myers board challenge

NEW YORK, Feb 28 Intellia Therapeutics Inc Chief Executive John Leonard, who U.S. drug maker Bristol-Myers Squibb Co said last week was nominated by hedge fund Starboard Value LP to sit on its board, is not affiliated with the effort, an Intellia spokeswoman said on Thursday.

Starboard joins opposition to Bristol-Myers' $74 billion Celgene deal

Activist hedge fund Starboard Value LP followed Bristol-Myers Squibb Co's second-largest investor, Wellington Management, in opposing the drugmaker's $74 billion purchase of biotech Celgene Corp on Thursday, sowing further doubt on what would be the largest pharmaceutical takeover ever.

Select another date: